Thinking About Entering The EU CBD Market? Some Food For Thought
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
You may also be interested in...
[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.
A wide-ranging study of low-dose cannabidiol supplementation, its regulation, efficacy and safety calls for improved legislation, guidelines and quality control together with clinical trials exploring the increasingly popular ingredient's therapeutic benefits.
HBW Insight speaks to Dragonfly's Hannah Skingle about the recent European turnaround on CBD regulation, as well as the UK firm's diversification into cosmetics.